Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes

被引：12
|
作者：
Taher, Ali T. [1 ]
Porter, John B. [2 ]
Kattamis, Antonis [3 ]
Viprakasit, Vip [4 ,5 ]
Cappellini, M. Domenica [6 ]
机构：
[1] Amer Univ Beirut, Dept Internal Med, Beirut 11072020, Lebanon
[2] UCL, Dept Haematol, London, England
[3] Univ Athens, Dept Pediat 1, Athens, Greece
[4] Mahidol Univ, Siriraj Hosp, Dept Pediat, Bangkok, Thailand
[5] Mahidol Univ, Siriraj Hosp, Thalassemia Ctr, Bangkok, Thailand
[6] Univ Milan, Ca Granda Fdn IRCCS, Dept Internal Med, Milan, Italy
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2016年 / 10卷
关键词：
BETA-THALASSEMIA; MYOCARDIAL IRON; OVERLOAD; INTERMEDIA; EXJADE(R); PROFILE; BURDEN;
D O I：
10.2147/DDDT.S117080
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
[No abstract available]
引用
收藏
页码：7073 / 7075
页数：3
相关论文
共 50 条
  • [1] Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes Reply
    Kontoghiorghes, George J.
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 7076 - 7078
  • [2] Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
    Kontoghiorghe, Christina N.
    Kontoghiorghes, George J.
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 465 - 481
  • [3] Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone
    Alymara, V
    Bourantas, D
    Chaidos, A
    Bouranta, P
    Gouva, M
    Vassou, A
    Tzouvara, E
    Bourantas, KL
    [J]. HEMATOLOGY JOURNAL, 2004, 5 (06) : 475 - 479
  • [4] Safety and efficacy of combining deferiprone and deferoxamine in iron chelation therapy in patients with thalassemia.
    Kattamis, A
    Kassou, C
    Ladis, V
    Berdoussi, H
    Papasotiriou, I
    Kattamis, C
    [J]. BLOOD, 2002, 100 (11) : 120A - 120A
  • [5] IRON-CHELATION THERAPY WITH ORAL DEFERIPRONE IN PATIENTS WITH THALASSEMIA MAJOR
    OLIVIERI, NF
    BRITTENHAM, GM
    MATSUI, D
    BERKOVITCH, M
    BLENDIS, LM
    CAMERON, RG
    MCCLELLAND, RA
    LIU, PP
    TEMPLETON, DM
    KOREN, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (14): : 918 - 922
  • [6] Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia
    Jamuar, Saumya S.
    Lai, Angeline H. M.
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (05) : 299 - 307
  • [7] Study of deferiprone or deferoxamine versus combination therapy in iron-loaded thalassemia patients in Taiwan.
    Peng, Ching-Tien
    Wu, Kang-Hsi
    Tsai, Chang-Hai
    Yang, Chao-Ping
    Wang, Lin-Yen
    Jang, Ren-Chin
    Hsiao, Chih-Cheng
    [J]. BLOOD, 2006, 108 (11) : 7B - 7B
  • [8] Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
    Olivieri, NF
    Brittenham, GM
    McLaren, CE
    Templeton, DM
    Cameron, RG
    McClelland, RA
    Burt, AD
    Fleming, KA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (07): : 417 - 423
  • [9] Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients
    Taher, A
    Sheikh-Taha, M
    Koussa, M
    Inati, A
    Neeman, R
    Mourad, F
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2001, 67 (01) : 30 - 34
  • [10] Renal Dysfunction in Patients with Beta-Thalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with Deferasirox
    Economou, Marina
    Printza, Nikoletta
    Teli, Aikaterini
    Tzimouli, Vassiliki
    Tsatra, Ioanna
    Papachristou, Fotis
    Athanassiou-Metaxa, Miranda
    [J]. ACTA HAEMATOLOGICA, 2010, 123 (03) : 148 - 152
12345